ESTRO 2025 - Abstract Book

S1751

Clinical – Upper GI

ESTRO 2025

Conclusion: 3 4 This retrospective study demonstrates that weekly carboplatin and paclitaxel have similar overall survival at 1 and 2 years to the standard of care chemo-radiotherapy. This opens up the question of whether we should be using this regime more frequently given its favourable toxicity profile. Further studies would be needed to determine long-term overall survival.

Keywords: Oesophageal Cancer

References: 1 Royal College of Radiologist Radiotherapy Dose Fractionation Fourth Edition. p40-47. 2 Hagen et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med 2012, 366, 2074 2084. 3 Crosby, T., Hurt, C., Falk, S. et al. Long-term Results and Recurrence Patterns from SCOPE-1: a phase II/III Randomised Trial of Definitive Chemoradiotherapy +/ − Cetuximab in Oesophageal Cancer. Br J Cancer 2017, 116, 709–716. 4 Owens, R. et al. Outcome of Weekly Carboplatin–Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum–Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review. Clinical Oncology 2020, 32, 121 – 130.

585

Digital Poster Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Esophageal Cancer Treated with Proton Beam Therapy Kenji Makita 1,2 , Hidehiro Hojo 1 , Takeshi Fujisawa 1 , Masaki Nakamura 1 , Hidekazu Oyoshi 1 , Kento Tomizawa 1 , Yuzheng Zhou 1 , Yume Koike 1 , Gyo Uchida 1 , Keiko Fukushi 1 , Saori Mishima 3 , Daisuke Kotani 3 , Takashi Kojima 3 , Sadamoto Zenda 1 1 Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan. 2 Department of Radiation Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. 3 Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan